Andy Batts
Long only, value, growth, momentum

Cepheid: A Global Growth Story At A Reasonable Price

The molecular diagnostics market, in which Cepheid (NASDAQ:CPHD) is a prominent player, is expected to grow rapidly at a 42% CAGR through 2017. Currently CPHD is trading at a multi-year high due to the immense industry growth prospects.

CPHD data by YCharts

CPHD has a broad range of tests that runs on its GeneXpert systems across infectious diseases, hospital acquired infections ("HAI"), women's health, genetics and oncology. I believe that two recent developments can drive the company's stock ~25% higher from the current level around $47. This article will focus on these developments.

Growth Opportunities from TB Detection

A few months ago the FDA approved Cepheid to market its Xpert MTB/RIF assay in the U.S. It's going to...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details